GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma
NCT: NCT07673692 · COMPLETED
Brief Summary
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-GBM can help detect a specific molecular type of brain tumour called IDH wildtype glioblastoma using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA). The main questions it aims to answer are: * How accurately can GliomaAI-GBM identify IDH wildtype glioblastoma from MRI scans? * How well does the system perform across data from different hospitals and patient groups? Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database. Participants will not be asked to do anything, as this study only uses previously collected imaging data.
Frequently Asked Questions
What is GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma?
GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma is a clinical trial registered under NCT07673692. Current status: COMPLETED.
What is the status of NCT07673692?
The current status of NCT07673692 (GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma) is: COMPLETED.
When did GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma start?
GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma started on 2017-03-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.